论文部分内容阅读
目的通过检测食道癌患者治疗前后外周血T细胞亚群表达水平,了解患者机体免疫功能状态。方法选用河北医科大学第四医院食道癌患者123例,其中淋巴结转移77例,未转移46例。抽取患者空腹外周血3ml,EDTA抗凝。采用流式细胞仪测定外周血CD3+,CD4+,CD8+,CD4+CD25+细胞亚群水平。结果治疗前CD3+,CD4+,CD8+,CD4+CD25+淋巴结转移和未转移组分别为58.22±6.70、29.79±3.31、21.81±3.31、3.34±1.31和56.43±8.35、28.75±4.62、23.99±3.93、4.44±1.48;治疗后分别为66.99±7.46、38.42±3.86、20.69±2.50、5.07±0.79和64.80±9.89、38.03±5.40、21.19±3.49、4.82±1.32。治疗前与治疗后组间比较差异无统计学意义(P>0.05)。CD4+治疗前后差异有统计学意义(P<0.05)。治疗前后CD4/CD8比值分别为1.26和1.82。讨论CD3+、CD4+、CD4+CD25+T治疗后略有上升,以CD4+上升较明显,而CD8+T略有下降,表明食道癌患者通过治疗,机体细胞免疫功能得到一定改善。
Objective To detect the expression of T lymphocyte subsets in peripheral blood of patients with esophageal cancer before and after treatment to understand the status of immune function in patients. Methods 123 cases of esophageal cancer were selected from the Fourth Hospital of Hebei Medical University, including 77 cases with lymph node metastasis and 46 cases without metastasis. Patients taking fasting peripheral blood 3ml, EDTA anticoagulant. The levels of CD3 +, CD4 +, CD8 + and CD4 + CD25 + subsets in peripheral blood were measured by flow cytometry. Results The levels of CD3 +, CD4 +, CD8 +, CD4 + CD25 + lymph node metastasis and non-metastasis before treatment were 58.22 ± 6.70,29.79 ± 3.31,21.81 ± 3.31,3.34 ± 1.31 and 56.43 ± 8.35,28.75 ± 4.62,23.99 ± 3.93,4.44 ± 1.48; after treatment, 66.99 ± 7.46, 38.42 ± 3.86, 20.69 ± 2.50, 5.07 ± 0.79 and 64.80 ± 9.89, 38.03 ± 5.40, 21.19 ± 3.49, 4.82 ± 1.32, respectively. There was no significant difference between pre-treatment and post-treatment groups (P> 0.05). The difference of CD4 + before and after treatment was statistically significant (P <0.05). CD4 / CD8 ratio before and after treatment was 1.26 and 1.82, respectively. Discussion CD3 +, CD4 +, CD4 + CD25 + T slightly increased after treatment to CD4 + increased significantly, while CD8 + T decreased slightly, indicating that patients with esophageal cancer through treatment, the body’s cellular immune function was improved.